Lupin announced that it has entered into a strategic partnership with Yabao Pharmaceutical Co., to meet the growing demand for quality drugs with paediatric formulations in the Chinese markets.

The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures. The latest Chinese paediatric pharmaceutical market report indicates that the market for paediatric drugs in China is expected to reach 210 billion CNY (US $ 33 billion) in 2021, growing at a rate of 9.23%.

Dr. Fabrice Egros, President - Corporate Development and Growth Markets, Lupin said, “We are excited about this partnership as it paves the way for us to bring quality paediatric formulations to the growing needs of patients in China. In addition to marketing our paediatric products in the Chinese market, we intend to expand our collaboration in other strategic therapeutics areas such as cardiometabolic, central nervous system and gastroenterology.”

Wei Ren, President of Yabao said, “We are very pleased to be partnering with Lupin to further strengthen Yabao’s leadership position in the paediatric market. Yabao strives to develop its paediatric pipeline to address the urgent unmet needs in the market and to serve paediatric patients. Moreover, Yabao also looks forward to expanding the collaboration with Lupin in other areas.”